TRITACE

This brand name is authorized in Nigeria. It is also authorized in Australia, Austria, Croatia, Hong Kong SAR China, Ireland, Israel, Mexico, Poland, Romania, Singapore, South Africa, UK.

Active ingredients

The drug TRITACE contains one active pharmaceutical ingredient (API):

1	Ramipril UNII L35JN3I7SJ - RAMIPRIL
	Ramiprilat, the active metabolite of the prodrug ramipril, inhibits the enzyme dipeptidylcarboxypeptidase I (synonyms: angiotensin-converting enzyme; kininase II). In plasma and tissue this enzyme catalyses the conversion of angiotensin I to the active vasoconstrictor substance angiotensin II, as well as the breakdown of the active vasodilator bradykinin. Reduced angiotensin II formation and inhibition of bradykinin breakdown lead to vasodilatation.
	Read more about Ramipril

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
04-2850	Tablet	Tritace 5 mg Tablets TAB 5 mg		01/03/2021
A4-4105	Tablet	Tritace 10 mg Tablets TAB 10 mg		26/08/2021

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TRITACE Tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C09AA05	Ramipril	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain
Discover more medicines within C09AA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	1316G, 1944H, 1945J, 1946K, 8470T
GB	Medicines & Healthcare Products Regulatory Agency	136013, 136014, 136015, 13802, 13806, 30401, 337642, 337648, 337650, 337652, 50106, 50109, 50112, 50115
HK	Department of Health Drug Office	36855, 36856
HR	Agencija za lijekove i medicinske proizvode	HR-H-251741808, HR-H-430835109, HR-H-569874847, HR-H-915616699
IE	Health Products Regulatory Authority	48017, 48023, 48042, 48061, 48122, 48166, 48175, 48189
IL	מִשְׂרַד הַבְּרִיאוּת	2658, 2659, 2660
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	040M92
NG	Registered Drug Product Database	04-2850, A4-4105
PL	Rejestru Produktów Leczniczych	100093257, 100093263, 100105871, 100403210, 100419078, 100419552, 100423826, 100424889, 100433664, 100447100, 100450128, 100454405, 100456819, 100467064, 100467096, 100468189, 100468437
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W62382001, W62382002, W62382003, W62382004, W62382005, W62382006, W62382007, W62382008, W62382009, W62382010, W62382011, W62382012, W62382013, W62382014, W62382015, W62382016, W62382017, W62382018, W62382019, W62447001, W62447002, W62447003, W62447004, W62447005, W62447006, W62447007, W62447008, W62447009, W62447010, W62447011, W62447012, W62447013, W62447014, W62447015, W62447016, W62447017, W62447018, W62447019, W62447020, W62447021, W62451001, W62451002, W62451003, W62451004, W62451005, W62451006, W62451007, W62451008, W62451009, W62451010, W62451011, W62451012, W62451013, W62451014, W62451015, W62451016, W62451017, W62451018, W62451019
SG	Health Sciences Authority	09591P, 09592P
ZA	Health Products Regulatory Authority	31/7.1.3/0667, W/7.1.3/235